A detailed history of State Street Corp transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 99,235 shares of RLMD stock, worth $35,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,235
Previous 105,879 6.28%
Holding current value
$35,724
Previous $317,000 1.26%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $4.36 $15,281 - $28,967
-6,644 Reduced 6.28%
99,235 $321,000
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $15,382 - $25,935
-5,250 Reduced 4.72%
105,879 $317,000
Q1 2024

May 15, 2024

SELL
$3.1 - $6.8 $12,710 - $27,880
-4,100 Reduced 3.56%
111,129 $516,000
Q3 2023

Nov 14, 2023

SELL
$2.48 - $3.79 $35,216 - $53,818
-14,200 Reduced 10.97%
115,229 $345,000
Q2 2023

Aug 14, 2023

SELL
$2.22 - $3.54 $936,100 - $1.49 Million
-421,667 Reduced 76.51%
129,429 $318,000
Q1 2023

May 15, 2023

BUY
$2.24 - $4.76 $124,013 - $263,527
55,363 Added 11.17%
551,096 $1.25 Million
Q4 2022

Feb 14, 2023

SELL
$2.17 - $35.84 $204,850 - $3.38 Million
-94,401 Reduced 16.0%
495,733 $1.73 Million
Q3 2022

Nov 15, 2022

SELL
$18.3 - $37.02 $202,233 - $409,108
-11,051 Reduced 1.84%
590,134 $21.8 Million
Q2 2022

Aug 15, 2022

BUY
$16.5 - $30.34 $2.57 Million - $4.72 Million
155,621 Added 34.93%
601,185 $11.4 Million
Q1 2022

May 16, 2022

BUY
$16.72 - $26.99 $2.04 Million - $3.3 Million
122,163 Added 37.77%
445,564 $12 Million
Q4 2021

Feb 14, 2022

SELL
$16.93 - $26.82 $41,817 - $66,245
-2,470 Reduced 0.76%
323,401 $7.29 Million
Q3 2021

Nov 15, 2021

BUY
$21.86 - $34.77 $343,355 - $546,132
15,707 Added 5.06%
325,871 $8.54 Million
Q2 2021

Aug 16, 2021

BUY
$29.55 - $39.15 $578,559 - $766,517
19,579 Added 6.74%
310,164 $9.93 Million
Q1 2021

May 17, 2021

SELL
$31.52 - $39.28 $437,308 - $544,970
-13,874 Reduced 4.56%
290,585 $10.2 Million
Q4 2020

Feb 16, 2021

BUY
$29.88 - $39.8 $63,883 - $85,092
2,138 Added 0.71%
304,459 $9.76 Million
Q3 2020

Nov 10, 2020

BUY
$34.42 - $43.78 $604,071 - $768,339
17,550 Added 6.16%
302,321 $11.4 Million
Q2 2020

Aug 14, 2020

BUY
$31.59 - $49.98 $8.73 Million - $13.8 Million
276,371 Added 3290.13%
284,771 $12.7 Million
Q1 2020

May 11, 2020

BUY
$23.78 - $50.12 $199,752 - $421,008
8,400 New
8,400 $287,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.3M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.